论文部分内容阅读
目的:建立头孢唑啉血清、髓核浓度的测定方法,观察其对人体椎间盘的渗透性。方法:10例腰椎间盘突出的患者,给予头孢唑啉2g静脉滴注30min,给药完毕后,即行手术取髓核,同时抽取静脉血,用高效液相色谱(HPLC)法测定髓核和血清的头孢唑啉浓度。结果:头孢唑啉在0.6~4.3μg·g-1及40~500mg·L-1范围内药物浓度(C)X和药物峰面积与内标物峰面积之比(A头孢唑啉/A内标)线性关系良好,血清标准曲线Y=1.7349X+0.0120,r=0.9998;髓核标准曲线Y=1.9098X-0.0088,r=0.9992。头孢唑啉在髓核中的药量分布个体差异较大,且髓核内药量与血清药浓间无相关性(r=0.122,P>0.05)。结论:本法可同时测定头孢唑啉在血清和髓核中的药物浓度,以满足临床药物监测的需要。
OBJECTIVE: To establish a method for the determination of cefazolin serum and nucleus pulposus and to observe its permeability to human disc. Methods: Ten patients with lumbar disc herniation were given intravenous infusion of cefazolin 2g for 30 minutes. After administration, nucleus pulposus was obtained by surgical operation. Venous blood was drawn at the same time. Nucleus pulposus and serum were determined by high performance liquid chromatography (HPLC) Of cefazolin concentration. Results: The ratio of the concentration of cefazolin in the range of 0.6 ~ 4.3 μg · g-1 and 40 ~ 500 mg · L-1 (C) X and the peak area of the drug to the internal standard peak area Standard curve Y = 1.7349X + 0.0120, r = 0.9998; nucleus standard curve Y = 1.9098X-0.0088, r = 0.9992. Cefazolin dose distribution in the nucleus of the individual differences are large, and the amount of drug in the nucleus pulposus has no correlation (r = 0.122, P> 0.05). Conclusion: This method can simultaneously determine cefazolin concentration in serum and nucleus in order to meet the needs of clinical drug monitoring.